Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons?: A critically appraised topic

Neurologist

Volumn 16, Issue 3, 2010, Pages 212-214

  Zarkou, Srijana ^a   Carter, Jonathan L ^a   Wellik, Kay E ^a   Demaerschalk, Bart M ^a   Wingerchuk, Dean M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Corticosteroids; Critically appraised topic; Evidence based medicine; Interferon beta; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; NEUTRALIZING ANTIBODY;

ADJUVANT THERAPY; ANTIBODY TITER; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

ADRENAL CORTEX HORMONES; ANTIBODIES, NEUTRALIZING; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 77952040311     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3181de4924     Document Type: Review

References (9)

1. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007; 68: 977-984. (Pubitemid 46569129)
2. Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on the use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-827.
3. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNSDrugs. 2009; 23: 379-396.
4. Shah A, Eggenberger E, Zivadinov R, et al. Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects. Neurotherapeutics. 2007; 4: 627-632.
5. Pozzilli C, Antonini G, Bagnato G, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis. J Neurol. 2002; 249: 50-56.
6. Cohen JA, Imrey PB, Calabresi PA, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009; 72: 535-541.
7. Hesse D, Frederiksen JL, Koch-Henriksen N, et al. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β. Eur J Neurol. 2009; 16: 43-47.
8. Ravenborg M, Bendtzen K, Christensen O, et al. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in antiinterferon beta antibody-positive patients with multiple sclerosis. Mult Scler. 2009; 15: 323-328.
9. Pachner AR, Brady J, Steiner I, et al. Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients. J Neurol. 2008; 255: 1815-1817.